Scholarlink

Background <p>This study aimed to evaluate the relationship between serum JAM-A levels and both hospital survival and six-month mortality in patients with acute ischemic stroke. It also aimed to investigate the correlation with the time elapsed from symptom onset to event.</p> Methods <p>This prospective, single-center study included 70 patients presenting to the emergency department with a diagnosis of acute ischemic stroke. Serum JAM-A levels were measured in venous blood samples taken at admission. Demographic characteristics, comorbidities, vascular occlusion localization, ASPECT score, and treatment methods applied were evaluated.</p> Results <p>Of the patients included in the study, 53 (75%) survived after treatment, while a total of 21 patients died at six-month of follow-up, resulting in a mortality rate of 30%. The mean age was 68.14 ± 11.95 years, and the mean age, BUN level, and AST level were significantly higher in the deceased patient group compared to the surviving patients (<i>P</i> = 0.012, <i>P</i> = 0.022, and <i>P</i> = 0.041, respectively). Distal vessel occlusions were more frequent in surviving patients, and a significant association was found between the localization of the vessel occlusion and clinical outcome (<i>P</i> = 0.011). In multivariate analysis, age (OR = 0.94; 95% CI: 0.90–0.98; <i>P</i> = 0.006) and the presence of distal occlusion (OR = 5.02; 95% CI: 1.55–16.23; <i>P</i> = 0.008) were found to be independent predictors. No association was found between JAM-A level and six-month mortality (<i>P</i> = 0.883), and its discriminatory power was weak in ROC analysis (AUC = 0.49). No significant correlation was found between the time elapsed from symptom onset to event and the JAM-A score (Pearson <i>r</i> = − 0.18, <i>P</i> = 0.129; Spearman rho = − 0.02, <i>P</i> = 0.870).</p> Conclusions <p>Serum JAM-A levels were found not to be significant in predicting hospital survival and six-month mortality in patients with acute ischemic stroke. Advanced age and localization of vascular occlusion emerged as important determinants of prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Investigation of the ability of JAM-A molecule to predict clinical outcome, mortality, and symptom onset in patients with acute stroke: a prospective observational single-center cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月4日

查看全文
  • Necmi Baykan,
  • Fatma Hancer Celi̇k,
  • Fatma Ünlü,
  • Muhammed Islam Ozer,
  • Elif Oztemur Ozer,
  • Mustafa Bilgili,
  • Derya Kocer,
  • Serhat Koyuncu,
  • Ömer Salt

摘要

Background

This study aimed to evaluate the relationship between serum JAM-A levels and both hospital survival and six-month mortality in patients with acute ischemic stroke. It also aimed to investigate the correlation with the time elapsed from symptom onset to event.

Methods

This prospective, single-center study included 70 patients presenting to the emergency department with a diagnosis of acute ischemic stroke. Serum JAM-A levels were measured in venous blood samples taken at admission. Demographic characteristics, comorbidities, vascular occlusion localization, ASPECT score, and treatment methods applied were evaluated.

Results

Of the patients included in the study, 53 (75%) survived after treatment, while a total of 21 patients died at six-month of follow-up, resulting in a mortality rate of 30%. The mean age was 68.14 ± 11.95 years, and the mean age, BUN level, and AST level were significantly higher in the deceased patient group compared to the surviving patients (P = 0.012, P = 0.022, and P = 0.041, respectively). Distal vessel occlusions were more frequent in surviving patients, and a significant association was found between the localization of the vessel occlusion and clinical outcome (P = 0.011). In multivariate analysis, age (OR = 0.94; 95% CI: 0.90–0.98; P = 0.006) and the presence of distal occlusion (OR = 5.02; 95% CI: 1.55–16.23; P = 0.008) were found to be independent predictors. No association was found between JAM-A level and six-month mortality (P = 0.883), and its discriminatory power was weak in ROC analysis (AUC = 0.49). No significant correlation was found between the time elapsed from symptom onset to event and the JAM-A score (Pearson r = − 0.18, P = 0.129; Spearman rho = − 0.02, P = 0.870).

Conclusions

Serum JAM-A levels were found not to be significant in predicting hospital survival and six-month mortality in patients with acute ischemic stroke. Advanced age and localization of vascular occlusion emerged as important determinants of prognosis.